Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …

Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a
therapeutic window. The recently approved mutant selective small-molecule cysteine …

Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …

The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Importance Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes
may accelerate precision medicine. Objective To assess whether a database that combines …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Diffuse gliomas are the most common malignant brain tumours in adults and include
glioblastomas and World Health Organization (WHO) grade II and grade III tumours …

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with
a poor prognosis and no known cure. Survival time is often short because of limited …